MissionSupport basic science, translational and clinical research through a competitive grants program that advances medical knowledge in the pathogenesis, treatment and prevention of infections.
BackgroundBasic scientific research continues to advance our knowledge and understanding of bacterial mechanisms of pathogenesis. However, the clinical applicability of these findings is not always apparent and correlative studies may not be readily available. The goal of this request for proposals is that results of the studies funded will lead to a better understanding of disease mechanisms and treatment options to enhance the clinical care of patients with infections.
There is a paucity of data in the literature regarding the association between the use of tigecycline for treatment of indicated infections and the impact on endogeneous microflora. Antimicrobials are known to alter endogeneous gut flora and may provide an environment for colonization by new pathogens or promote resistance in the normal flora.
Clostridium difficile is a ubiquitous anaerobic bacterium that has become a highly prevalent nosocomial pathogen. Key risk factors for the
development of C. difficile are antibiotic exposure, hospital stays, immunosuppression, increased age and previous CDI. It is unclear the association between tigecycline and C. difficile. As a result, there are unmet scientific needs to understand the relationship between tigecycline and C. difficile.
2011 Research TopicBasic and Translational Research to Understand the Impact of Antimicrobials on Endogenous Gastrointestinal Microflora
Research RequirementsAn applicant should have a strong academic career interest within the areas of focus and should consider the following components when developing their research proposals:
- Support basic scientific research involving tigecycline
- Enhance the scientific understanding of tigecycline in relation to the proliferation, selection pressure and relapse of Clostridium difficile in relation to the on-label use of tigecycline in approved indications
- Translate the resulting knowledge to bridge the gap between bench and bedside
Available AwardsPfizer is funding research awards up to a maximum of $100,000 USD/CDN each, inclusive of overhead costs for one year. Application is open to
US and Canadian investigators. Selection of awardees will be performed by an independent, external expert panel comprised of medical and